Site icon pharmaceutical daily

Hypotension – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hypotension
– Pipeline Review, H1 2019”
drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Hypotension – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Hypotension (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Hypotension (Cardiovascular) pipeline guide
also reviews of key players involved in therapeutic development for
Hypotension and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Phase III, Phase II, Phase I and Unknown stages are 1,
2, 1, 2 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Scope

Reasons to Buy

Featured News & Press Releases

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/91um1g

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs

Exit mobile version